| Year |
Citation |
Score |
| 2024 |
Hartung HP, Berger T, Bermel RA, Brochet B, Carroll WM, Holmøy T, Karabudak R, Killestein J, Nos C, Patti F, Perrin Ross A, Vanopdenbosch L, Vollmer T, Buffels R, Garas M, ... ... Freedman MS, et al. ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial. Journal of Neurology. PMID 38649522 DOI: 10.1007/s00415-024-12326-z |
0.313 |
|
| 2024 |
Kalincik T, Sharmin S, Roos I, Massey J, Sutton I, Withers B, Freedman MS, Atkins H, Krasulova E, Kubala Havrdova E, Trneny M, Kozak T, Burman J, Macdonell R, Torkildsen Ø, et al. Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 38538060 DOI: 10.1136/jnnp-2023-332790 |
0.362 |
|
| 2024 |
Freedman MS, Gnanapavan S, Booth RA, Calabresi PA, Khalil M, Kuhle J, Lycke J, Olsson T. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. Ebiomedicine. 101: 104970. PMID 38354532 DOI: 10.1016/j.ebiom.2024.104970 |
0.328 |
|
| 2024 |
Freedman MS, Coyle PK, Hellwig K, Singer B, Wynn D, Weinstock-Guttman B, Markovic-Plese S, Galazka A, Dangond F, Korich J, Reder AT. Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives. Neurology and Therapy. PMID 38206453 DOI: 10.1007/s40120-023-00565-7 |
0.332 |
|
| 2023 |
Cardwell K, Awadia Z, McKenna O, Venasse M, Hume T, Ludgate J, Freedman M, Finlayson M, Latimer-Cheung A, Pilutti LA, Fakolade A. Physical activity together for MS (PAT-MS): Secondary outcomes of a randomized controlled feasibility trial. Multiple Sclerosis and Related Disorders. 82: 105399. PMID 38184911 DOI: 10.1016/j.msard.2023.105399 |
0.326 |
|
| 2023 |
Fakolade A, Awadia Z, Cardwell K, McKenna O, Venasse M, Hume T, Ludgate J, Freedman MS, Finlayson M, Latimer-Cheung AE, Pilutti LA. Physical Activity Together for Multiple Sclerosis (PAT-MS): A randomized controlled feasibility trial of a dyadic behaviour change intervention. Contemporary Clinical Trials Communications. 36: 101222. PMID 37928934 DOI: 10.1016/j.conctc.2023.101222 |
0.324 |
|
| 2023 |
Singer BA, Arnold DL, Drulovic J, Freedman MS, Gold R, Gudesblatt M, Jasinska E, LaGanke CC, Naismith RT, Negroski D, Oh J, Hernandez Perez MA, Selmaj K, Then Bergh F, Wundes A, et al. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585231205708. PMID 37905526 DOI: 10.1177/13524585231205708 |
0.357 |
|
| 2023 |
Sohaei D, Thebault S, Avery LM, Batruch I, Lam B, Xu W, Saadeh RS, Scarisbrick IA, Diamandis EP, Prassas I, Freedman MS. Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics. 20: 33. PMID 37644477 DOI: 10.1186/s12014-023-09418-9 |
0.301 |
|
| 2023 |
Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, di Cantogno EV. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegenerative Disease Management. PMID 37535336 DOI: 10.2217/nmt-2023-0018 |
0.352 |
|
| 2023 |
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann AK, Havrdova EK, et al. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. Jama Neurology. 80: 702-713. PMID 37437240 DOI: 10.1001/jamaneurol.2023.1184 |
0.308 |
|
| 2023 |
Spain RI, Hildebrand A, Waslo CS, Rooney WD, Emmons J, Schwartz DL, Freedman MS, Paz Soldan MM, Repovic P, Solomon AJ, Rinker J, Wallin M, Haselkorn JK, Stuve O, Gross RH, et al. Processing speed and memory test performance are associated with different brain region volumes in Veterans and others with progressive multiple sclerosis. Frontiers in Neurology. 14: 1188124. PMID 37360346 DOI: 10.3389/fneur.2023.1188124 |
0.323 |
|
| 2023 |
Jiang T, Ziemssen T, Wray S, Shen C, Söderbärg K, Lewin JB, Božin I, Freedman MS. Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis. Cns Drugs. PMID 37155132 DOI: 10.1007/s40263-023-01002-x |
0.318 |
|
| 2023 |
Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585231161494. PMID 37012898 DOI: 10.1177/13524585231161494 |
0.349 |
|
| 2022 |
Puyade M, Brunet F, Carolina R, Fergusson N, Makedonov I, Freedman MS, Atkins H. Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol. Current Protocols. 2: e437. PMID 35594180 DOI: 10.1002/cpz1.437 |
0.336 |
|
| 2022 |
Battaglini M, Vrenken H, Tappa Brocci R, Gentile G, Luchetti L, Versteeg A, Freedman MS, Uitdehaag BMJ, Kappos L, Comi G, Seitzinger A, Jack D, Sormani MP, Barkhof F, De Stefano N. Evolution from a first clinical demyelinating even to multiple sclerosis in the REFLEX trial Regional susceptibility in the conversion to multiple sclerosis at disease onset and their amenability to subcutaneous interferon beta-1a. European Journal of Neurology. PMID 35274413 DOI: 10.1111/ene.15314 |
0.332 |
|
| 2022 |
Tremblay F, Ansari Y, Remaud A, Freedman MS. Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis. Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 136: 69-81. PMID 35149266 DOI: 10.1016/j.clinph.2022.01.125 |
0.313 |
|
| 2022 |
Manuel Escobar J, Cortese M, Edan G, Freedman MS, Hartung HP, Montalbán X, Sandbrink R, Radü EW, Barkhof F, Wicklein EM, Kappos L, Ascherio A, Munger KL. Body mass index as a predictor of MS activity and progression among participants in BENEFIT. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585211061861. PMID 34994579 DOI: 10.1177/13524585211061861 |
0.302 |
|
| 2021 |
Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, Ramo Tello C, Schiavetti I, ... ... Freedman MS, et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. The Lancet. Neurology. 20: 917-929. PMID 34687636 DOI: 10.1016/S1474-4422(21)00301-X |
0.312 |
|
| 2021 |
Weinstock-Guttman B, Bermel R, Cutter G, Freedman MS, Leist TP, Ma X, Kile D, Musch B, Reder AT, Wolinsky JS. Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585211035740. PMID 34382875 DOI: 10.1177/13524585211035740 |
0.33 |
|
| 2021 |
Thebault S, Booth RA, Rush CA, MacLean H, Freedman MS. Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation. Frontiers in Neuroscience. 15: 654942. PMID 33841093 DOI: 10.3389/fnins.2021.654942 |
0.32 |
|
| 2021 |
Roy R, Alotaibi AA, Freedman MS. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. Cns Drugs. PMID 33797705 DOI: 10.1007/s40263-021-00798-w |
0.389 |
|
| 2021 |
Freedman MS, Coyle PK, Comi G, L Scarberry S, Damian D, Hyvert Y, Dangond F, Galazka A, Jack D, Lebson LA, Leist TP. Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 7: 2055217321990852. PMID 33717501 DOI: 10.1177/2055217321990852 |
0.332 |
|
| 2021 |
Thebault S, Bose G, Booth R, Freedman MS. Serum neurofilament light in MS: The first true blood-based biomarker? Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458521993066. PMID 33565908 DOI: 10.1177/1352458521993066 |
0.317 |
|
| 2020 |
Freedman M, Gnanapavan S. Letter to the Editor: Consensus Statement on Neurofilament Proteins in Multiple Sclerosis Under Development by Consortium of Multiple Sclerosis Centers (CMSC) Expert Panel. International Journal of Ms Care. 22: 294. PMID 33424486 DOI: 10.7224/1537-2073.2020-140 |
0.316 |
|
| 2020 |
Horáková D, Boster A, Bertolotto A, Freedman MS, Firmino I, Cavalier SJ, Jacobs AK, Thangavelu K, Daizadeh N, Poole EM, Baker DP, Margolin DH, Ziemssen T. Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 6: 2055217320972137. PMID 33414927 DOI: 10.1177/2055217320972137 |
0.373 |
|
| 2020 |
Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Neurology. 19: 988-997. PMID 33222767 DOI: 10.1016/S1474-4422(20)30347-1 |
0.345 |
|
| 2020 |
Freedman MS, Devonshire V, Duquette P, Giacomini PS, Giuliani F, Levin MC, Montalban X, Morrow SA, Oh J, Rotstein D, Yeh EA. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 47: 437-455. PMID 32654681 DOI: 10.1017/cjn.2020.66 |
0.327 |
|
| 2020 |
Maghzi AH, Houtchens MK, Preziosa P, Ionete C, Beretich BD, Stankiewicz JM, Tauhid S, Cabot A, Berriosmorales I, Schwartz THW, Sloane JA, Freedman MS, Filippi M, Weiner HL, Bakshi R. COVID-19 in teriflunomide-treated patients with multiple sclerosis. Journal of Neurology. PMID 32494856 DOI: 10.1007/S00415-020-09944-8 |
0.355 |
|
| 2020 |
Bose G, Thebault S, Rush CA, Atkins HL, Freedman MS. Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458520917936. PMID 32364422 DOI: 10.1177/1352458520917936 |
0.344 |
|
| 2020 |
Thebault S, Lee H, Bose G, Tessier D, Abdoli M, Bowman M, Berard J, Walker L, Rush CA, MacLean H, Booth RA, Narayanan S, Arnold DL, Tabard-Cossa V, Atkins HL, ... ... Freedman MS, et al. Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Annals of Clinical and Translational Neurology. PMID 32304358 DOI: 10.1002/acn3.51045 |
0.303 |
|
| 2020 |
Ziemssen T, Piani-Meier D, Bennett B, Johnson C, Tinsley K, Trigg A, Hach T, Dahlke F, Tomic D, Tolley C, Freedman MS. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study. Journal of Medical Internet Research. 22: e16932. PMID 32049062 DOI: 10.2196/16932 |
0.333 |
|
| 2020 |
Bose G, Freedman MS. Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458519887324. PMID 31965903 DOI: 10.1177/1352458519887324 |
0.362 |
|
| 2020 |
Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, Selmaj K, Bidollari I, Chen H, Hanna J, Leigh-Pemberton R, Lopez-Bresnahan M, Lyons J, Miller C, Rezendes D, et al. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. Cns Drugs. PMID 31953790 DOI: 10.1007/s40263-020-00700-0 |
0.302 |
|
| 2019 |
Van Wijmeersch B, Singer BA, Boster A, Broadley S, Fernández Ó, Freedman MS, Izquierdo G, Lycke J, Pozzilli C, Sharrack B, Steingo B, Wiendl H, Wray S, Ziemssen T, Chung L, et al. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458519881759. PMID 31675266 DOI: 10.1177/1352458519881759 |
0.375 |
|
| 2019 |
Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS, et al. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 20: 263. PMID 31072380 DOI: 10.1186/s13063-019-3346-z |
0.378 |
|
| 2019 |
Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, et al. AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR TREATMENT-REFRACTORY RELAPSING MULTIPLE SCLEROSIS: POSITION STATEMENT FROM THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30794930 DOI: 10.1016/j.bbmt.2019.02.014 |
0.343 |
|
| 2018 |
Bose G, Atkins HL, Bowman M, Freedman MS. Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518802544. PMID 30251913 DOI: 10.1177/1352458518802544 |
0.356 |
|
| 2018 |
Alnajashi HA, Alshamrani FJ, Freedman MS. Tolerability and discontinuation rates in teriflunomide-treated patients. A real-world clinical experience. Neurosciences (Riyadh, Saudi Arabia). 23: 204-207. PMID 30007995 |
0.317 |
|
| 2018 |
Darlington PJ, Stopnicki B, Touil T, Doucet JS, Fawaz L, Roberts ME, Boivin MN, Arbour N, Freedman MS, Atkins HL, Bar-Or A. Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis. Frontiers in Immunology. 9: 834. PMID 29867923 DOI: 10.3389/fimmu.2018.00834 |
0.405 |
|
| 2018 |
Burton JM, Freedman MS. The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis. Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society. 38: 210-216. PMID 29750735 DOI: 10.1097/WNO.0000000000000659 |
0.393 |
|
| 2018 |
Rush CA, Atkins HL, Freedman MS. Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine. PMID 29610145 DOI: 10.1101/cshperspect.a029082 |
0.367 |
|
| 2018 |
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. The Lancet. Neurology. PMID 29545067 DOI: 10.1016/S1474-4422(18)30069-3 |
0.435 |
|
| 2018 |
Sormani MP, Freedman M, Aldridge J, Marhardt K, Stefano ND. Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) Score Predicts Long-term Clinical Disease Activity (CDA)-free Status and Disability Progression in Subcutaneous Interferon Beta-1a (scifnβ-1a)-treated Patients Multiple Sclerosis and Related Disorders. 26: 240-241. DOI: 10.1016/J.Msard.2018.10.037 |
0.301 |
|
| 2018 |
Khan S, Schafhauser J, Davila L, Saleh F, Hodgins S, Hilliker C, Freedman M, Courtman D. The mesenchymal stem cell therapy for canadians with multiple sclerosis (MESCAMS) clinical trial: Cell manufacturing of autologous bone marrow-derived mscs in ottawa Cytotherapy. 20: S42. DOI: 10.1016/J.Jcyt.2018.02.108 |
0.355 |
|
| 2017 |
Freedman MS, Leist TP, Comi G, Cree BA, Coyle PK, Hartung HP, Vermersch P, Damian D, Dangond F. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 3: 2055217317732802. PMID 29051829 DOI: 10.1177/2055217317732802 |
0.353 |
|
| 2017 |
Atkins HL, Freedman MS. Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 28822119 DOI: 10.1007/s13311-017-0564-5 |
0.415 |
|
| 2017 |
Lee H, Nakamura K, Narayanan S, Brown R, Chen J, Atkins HL, Freedman MS, Arnold DL. Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458517715811. PMID 28617152 DOI: 10.1177/1352458517715811 |
0.309 |
|
| 2017 |
Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A. Sodium intake and multiple sclerosis activity and progression in BENEFIT. Annals of Neurology. PMID 28556498 DOI: 10.1002/Ana.24965 |
0.331 |
|
| 2017 |
Freedman MS, Wolinsky JS, Comi G, Kappos L, Olsson TP, Miller AE, Thangavelu K, Benamor M, Truffinet P, O'Connor PW. The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458517695468. PMID 28304217 DOI: 10.1177/1352458517695468 |
0.334 |
|
| 2017 |
Freedman MS, Vermersch P, Damian D, Dangond F. Analyse rétrospective d’efficacité chez les patients atteints de (SEP) répondant aux critères de McDonald 2010 dans l’étude ORACLE-MS Revue Neurologique. 173: S115-S116. DOI: 10.1016/J.NEUROL.2017.01.197 |
0.308 |
|
| 2017 |
Macdonell R, Freedman M, Xu X, Vucic S, Truffinet P, Benamor M, Thangavelu K, Miller A. Efficacy and safety of teriflunomide in Chinese patients with relapsing forms of MS: A subgroup analysis of the phase 3 tower study Journal of the Neurological Sciences. 381: 135. DOI: 10.1016/J.Jns.2017.08.403 |
0.389 |
|
| 2016 |
Freedman MS. Multiple sclerosis: Is there a safe time to discontinue therapy in MS? Nature Reviews. Neurology. 13: 10-11. PMID 28028316 DOI: 10.1038/nrneurol.2016.192 |
0.343 |
|
| 2016 |
Alshamrani F, Alnajashi H, Freedman M. Radiologically isolated syndrome: watchful waiting vs. active treatment. Expert Review of Neurotherapeutics. PMID 27830953 DOI: 10.1080/14737175.2017.1259568 |
0.439 |
|
| 2016 |
Khoury SJ, Rochon J, Ding L, Byron M, Ryker K, Tosta P, Gao W, Freedman MS, Arnold DL, Sayre PH, Smilek DE. ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 27481207 DOI: 10.1177/1352458516662727 |
0.391 |
|
| 2016 |
Menon S, Zhu F, Shirani A, Oger J, Freedman MS, Tremlett H. Disability progression in aggressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 27325603 DOI: 10.1177/1352458516653273 |
0.375 |
|
| 2016 |
Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, Hutton B, ... ... Freedman MS, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet (London, England). PMID 27291994 DOI: 10.1016/S0140-6736(16)30169-6 |
0.319 |
|
| 2016 |
Freedman MS, Rush CA. Severe, Highly Active, or Aggressive Multiple Sclerosis. Continuum (Minneapolis, Minn.). 22: 761-784. PMID 27261681 DOI: 10.1212/CON.0000000000000331 |
0.367 |
|
| 2016 |
Lee H, Narayanan S, Brown RA, Chen JT, Atkins HL, Freedman MS, Arnold DL. Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 27246142 DOI: 10.1177/1352458516650992 |
0.306 |
|
| 2016 |
Torres C, Hogan M, Patro S, Chakraborty S, Nguyen T, Thornhill R, Freedman M, Bussiere M, Dabirzadeh H, Schwarz BA, Belanger S, Legault-Kingstone L, Schweitzer M, Lum C. Extracranial Venous abnormalities: A true pathological finding in patients with multiple sclerosis or an anatomical variant? European Radiology. PMID 27011374 DOI: 10.1007/S00330-016-4314-6 |
0.441 |
|
| 2016 |
Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet (London, England). PMID 26827074 DOI: 10.1016/S0140-6736(15)01314-8 |
0.325 |
|
| 2015 |
Munger KL, Fitzgerald KC, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Suarez G, Radue EW, Sandbrink R, Kappos L, Pohl C, Ascherio A. No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. Neurology. 85: 1694-701. PMID 26453645 DOI: 10.1212/Wnl.0000000000002099 |
0.339 |
|
| 2015 |
Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nature Reviews. Neurology. 11: 379-89. PMID 26032396 DOI: 10.1038/nrneurol.2015.85 |
0.385 |
|
| 2015 |
Barnes D, Leist T, Freedman M, Olsson T, Miller A, Wolinsky J, O'Connor P, Benamor M, Truffinet P, Comi G. SAFETY AND TOLERABILITY OF TERIFLUNOMIDE IN CLINICAL STUDIES Journal of Neurology, Neurosurgery & Psychiatry. 86: e4.26-e4. DOI: 10.1136/Jnnp-2015-312379.121 |
0.314 |
|
| 2015 |
Weller B, Comi G, Freedman M, Kappos L, Miller A, Olsson T, Wolinsky J, Benamor M, Truffinet P, O'Connor P. EFFECT OF TERIFLUNOMIDE ON LYMPHOCYTE AND NEUTROPHIL COUNTS Journal of Neurology, Neurosurgery & Psychiatry. 86: e4.25-e4. DOI: 10.1136/Jnnp-2015-312379.120 |
0.303 |
|
| 2015 |
Khan S, Germain CS, Hodgins S, Hilliker C, Freedman M, Courtman DW. Preparation of autologous bone marrow-derived mesenchymal stem cells (MSCs) for mesenchymal stem cell therapy for canadians with multiple sclerosis (MESCAMS) trial Cytotherapy. 17: S56. DOI: 10.1016/J.Jcyt.2015.03.500 |
0.33 |
|
| 2014 |
Stuve O, Hartung HP, Freedman M, Li D, Hemmer B, Kappos L, Rieckmann P, Montalban X, Ziemssen T, Selmaj K. Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 3: 754-5. PMID 25891595 DOI: 10.1016/J.Msard.2014.09.190 |
0.332 |
|
| 2014 |
Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Multiple Sclerosis and Related Disorders. 3: 696-704. PMID 25891548 DOI: 10.1016/j.msard.2014.08.002 |
0.336 |
|
| 2014 |
Freedman MS, Comi G, De Stefano N, Barkhof F, Polman CH, Uitdehaag BM, Lehr L, Stubinski B, Kappos L. Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. Multiple Sclerosis and Related Disorders. 3: 147-55. PMID 25878002 DOI: 10.1016/J.Msard.2013.07.001 |
0.315 |
|
| 2014 |
Freedman MS. Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis. Expert Opinion On Biological Therapy. 14: 1207-14. PMID 24965353 DOI: 10.1517/14712598.2014.924496 |
0.376 |
|
| 2014 |
Freedman MS. Multiple sclerosis: Does aggressive MS warrant aggressive treatment? Nature Reviews. Neurology. 10: 368-70. PMID 24890645 DOI: 10.1038/nrneurol.2014.98 |
0.356 |
|
| 2014 |
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, ... Freedman MS, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 83: 278-86. PMID 24871874 DOI: 10.1212/Wnl.0000000000000560 |
0.319 |
|
| 2014 |
Correale J, Abad P, Alvarenga R, Alves-Leon S, Armas E, Barahona J, Buzó R, Corona T, Cristiano E, Gracia F, Bonitto JG, MacÃas MA, Soto A, Vizcarra D, Freedman MS. Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization. Journal of the Neurological Sciences. 339: 196-206. PMID 24607335 DOI: 10.1016/j.jns.2014.02.017 |
0.309 |
|
| 2014 |
Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. The Lancet. Neurology. 13: 257-67. PMID 24502830 DOI: 10.1016/S1474-4422(14)70005-5 |
0.363 |
|
| 2014 |
Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Neurology. 13: 247-56. PMID 24461574 DOI: 10.1016/S1474-4422(13)70308-9 |
0.319 |
|
| 2014 |
Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. Jama Neurology. 71: 306-14. PMID 24445558 DOI: 10.1001/Jamaneurol.2013.5993 |
0.309 |
|
| 2014 |
Freedman MS, De Stefano N, Barkhof F, Polman CH, Comi G, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Lehr L, Stubinski B, Jack DL, Kappos L. Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study. Journal of Neurology. 261: 490-9. PMID 24413638 DOI: 10.1007/S00415-013-7222-6 |
0.329 |
|
| 2014 |
Al Tahan AM, Alsharoqi I, Bohlega SA, Dahdaleh M, Daif A, Deleu D, Esmat K, Giampaolo D, Freedman MS, Gwilt M, Hosny H, Inshasi JS, Aljumah M, Khalifa A, Pakdaman H, et al. Characteristics of multiple sclerosis in the Middle East with special reference to the applicability of international guidelines to the region. The International Journal of Neuroscience. 124: 635-41. PMID 24228830 DOI: 10.3109/00207454.2013.865620 |
0.319 |
|
| 2013 |
Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. Journal of Clinical & Cellular Immunology. 4. PMID 24363961 DOI: 10.4172/2155-9899.1000152 |
0.423 |
|
| 2013 |
Freedman MS. Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Therapeutic Advances in Chronic Disease. 4: 192-205. PMID 23997924 DOI: 10.1177/2040622313492810 |
0.348 |
|
| 2013 |
Grand'Maison F, Bhan V, Freedman MS, Myles ML, Patry DG, Selchen DH, Moriarty P, Traboulsee AL. Utility of the Canadian Treatment Optimization Recommendations (TOR) in MS care. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 40: 527-35. PMID 23786735 |
0.305 |
|
| 2013 |
Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS, Tremlett H. Characterising aggressive multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 84: 1192-8. PMID 23744892 DOI: 10.1136/Jnnp-2013-304951 |
0.381 |
|
| 2013 |
Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, Morgenthau D, Lapierre Y. Treatment optimization in MS: Canadian MS Working Group updated recommendations. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 40: 307-23. PMID 23603165 DOI: 10.1017/S0317167100014244 |
0.32 |
|
| 2013 |
Darlington PJ, Touil T, Doucet JS, Gaucher D, Zeidan J, Gauchat D, Corsini R, Kim HJ, Duddy M, Jalili F, Arbour N, Kebir H, Chen J, Arnold DL, Bowman M, ... ... Freedman MS, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Annals of Neurology. 73: 341-54. PMID 23463494 DOI: 10.1002/Ana.23784 |
0.57 |
|
| 2013 |
Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells as treatment for MS - progress to date. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 515-9. PMID 23124791 DOI: 10.1177/1352458512464686 |
0.386 |
|
| 2013 |
Comi G, Freedman M, Kappos L, Miller A, Olsson T, Wolinsky J, Delhay J, Li J, Truffinet P, O’Connor P. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: Results from the Tower Study Journal of the Neurological Sciences. 333: e376. DOI: 10.1016/j.jns.2013.07.1370 |
0.353 |
|
| 2012 |
Selchen D, Bhan V, Blevins G, Devonshire V, Duquette P, Grand'Maison F, Kremenchutzky M, Lapierre Y, Li D, von Riedemann SJ, Freedman M. MS, MRI, and the 2010 McDonald criteria: a Canadian expert commentary. Neurology. 79: S1-15. PMID 23212280 DOI: 10.1212/Wnl.0B013E318277D144 |
0.426 |
|
| 2012 |
Freedman M. The use of natalizumab for treatment of MS: do the risks still outweigh the gains? The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 39: 559-60. PMID 22931689 DOI: 10.1017/S0317167100015213 |
0.387 |
|
| 2012 |
Greene DN, Schmidt RL, Wilson AR, Freedman MS, Grenache DG. Cerebrospinal fluid myelin basic protein is frequently ordered but has little value: a test utilization study. American Journal of Clinical Pathology. 138: 262-72. PMID 22904139 DOI: 10.1309/AJCPCYCH96QYPHJM |
0.335 |
|
| 2012 |
Darlington P, Ouamara N, Stonebridge I, Rozenberg A, Freedman M, Antel J, Bar-Or A. Fingolimod Treatment in Multiple Sclerosis Increases the Ability of Circulating T Cells To Regulate Pro-Inflammatory Th1 and Th17 T Cell Responses (S31.003) Neurology. 78: S31.003-S31.003. DOI: 10.1212/Wnl.78.1_Meetingabstracts.S31.003 |
0.449 |
|
| 2012 |
Miller A, Lublin F, O'Connor P, Wolinsky J, Comi G, Kappos L, Freedman M, Olsson T, Dive-Pouletty C, Bego-Le-Bagousse G, Confavreux C. Effect of Teriflunomide on Relapses with Sequelae and Relapse Leading to Hospitalization in a Population with Relapsing Forms of Multiple Sclerosis: Results from the TEMSO Study (S30.003) Neurology. 78: S30.003-S30.003. DOI: 10.1212/Wnl.78.1_Meetingabstracts.S30.003 |
0.382 |
|
| 2012 |
Stuve O, Selmaj K, Li D, Hartung H, Hemmer B, Kappos L, Freedman M, Rieckmann P, Montalban X, Zhang Auberson L, Pohlmann H, Mercier F, Dahlke F, Wallstrom E. BAF312, a Selective Sphingosine-1-Phosphate Receptor Modulator Improves MRI and Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis (RRMS) (S30.001) Neurology. 78: S30.001-S30.001. DOI: 10.1212/Wnl.78.1_Meetingabstracts.S30.001 |
0.306 |
|
| 2012 |
Freedman M, O'Connor P, Wolinsky J, Confavreux C, Comi G, Kappos L, Olsson T, Truffinet P, Dukovic D, Miller A. Teriflunomide Increases the Proportion of Patients Free from Disease Activity in the TEMSO Phase III Study (PD5.007) Neurology. 78: PD5.007-PD5.007. DOI: 10.1212/Wnl.78.1_Meetingabstracts.Pd5.007 |
0.36 |
|
| 2011 |
Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, et al. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology. 77: 835-43. PMID 21849647 DOI: 10.1212/Wnl.0B013E31822C90D7 |
0.325 |
|
| 2011 |
Acaster S, Swinburn P, Wang C, Stemper B, Beckmann K, Knappertz V, Pohl C, Sandbrink R, Gondek K, Edan G, Kappos L, Freedman M, Hartung HP, Arnason B, Comi G, et al. Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 1504-13. PMID 21757536 DOI: 10.1177/1352458511414039 |
0.424 |
|
| 2011 |
Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. The Lancet. Neurology. 10: 649-56. PMID 21683930 DOI: 10.1016/S1474-4422(11)70121-1 |
0.325 |
|
| 2011 |
Chen Z, Freedman MS. γδ T cells and multiple sclerosis: Friends, foes, or both? Autoimmunity Reviews. 10: 364-7. PMID 21195807 DOI: 10.1016/J.Autrev.2010.12.005 |
0.592 |
|
| 2010 |
Darlington PJ, Boivin MN, Renoux C, François M, Galipeau J, Freedman MS, Atkins HL, Cohen JA, Solchaga L, Bar-Or A. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Annals of Neurology. 68: 540-5. PMID 20661924 DOI: 10.1002/ana.22065 |
0.328 |
|
| 2010 |
Khan O, Filippi M, Freedman MS, Barkhof F, Dore-Duffy P, Lassmann H, Trapp B, Bar-Or A, Zak I, Siegel MJ, Lisak R. Chronic cerebrospinal venous insufficiency and multiple sclerosis. Annals of Neurology. 67: 286-90. PMID 20373339 DOI: 10.1002/Ana.22001 |
0.581 |
|
| 2010 |
Vosoughi R, Freedman MS. Therapy of MS. Clinical Neurology and Neurosurgery. 112: 365-85. PMID 20362388 DOI: 10.1016/j.clineuro.2010.03.010 |
0.318 |
|
| 2010 |
Pasquini MC, Griffith LM, Arnold DL, Atkins HL, Bowen JD, Chen JT, Freedman MS, Kraft GH, Mancardi GL, Martin R, Muraro PA, Nash RA, Racke MK, Storek J, Saccardi R. Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 1076-83. PMID 20304084 DOI: 10.1016/j.bbmt.2010.03.012 |
0.361 |
|
| 2010 |
Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, Scolding N, Slavin S, Le Blanc K, Uccelli A. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 503-10. PMID 20086020 DOI: 10.1177/1352458509359727 |
0.322 |
|
| 2009 |
Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology. 66: 460-71. PMID 19847908 DOI: 10.1002/Ana.21867 |
0.542 |
|
| 2009 |
Freedman MS, Cohen B, Dhib-Jalbut S, Jeffery D, Reder AT, Sandberg-Wollheim M, Weinstock-Guttman B. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Current Medical Research and Opinion. 25: 2459-70. PMID 19678753 DOI: 10.1185/03007990903158364 |
0.358 |
|
| 2009 |
Atkins H, Freedman M. Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis. Methods in Molecular Biology (Clifton, N.J.). 549: 231-46. PMID 19378207 DOI: 10.1007/978-1-60327-931-4_16 |
0.445 |
|
| 2009 |
Costello F, Hodge W, Pan YI, Freedman M, DeMeulemeester C. Differences in retinal nerve fiber layer atrophy between multiple sclerosis subtypes. Journal of the Neurological Sciences. 281: 74-9. PMID 19303605 DOI: 10.1016/J.Jns.2009.02.354 |
0.343 |
|
| 2009 |
MacLean HJ, Freedman MS. Multiple sclerosis: following clues from cause to cure. The Lancet. Neurology. 8: 6-8. PMID 19081501 DOI: 10.1016/S1474-4422(08)70272-2 |
0.345 |
|
| 2008 |
Darlington PJ, Podjaski C, Horn KE, Costantino S, Blain M, Saikali P, Chen Z, Baker KA, Newcombe J, Freedman M, Wiseman PW, Bar-Or A, Kennedy TE, Antel JP. Innate immune-mediated neuronal injury consequent to loss of astrocytes. Journal of Neuropathology and Experimental Neurology. 67: 590-9. PMID 18520777 DOI: 10.1097/Nen.0B013E3181772Cf6 |
0.618 |
|
| 2008 |
Chen Z, Freedman MS. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis. Clinical Immunology (Orlando, Fla.). 128: 219-27. PMID 18501678 DOI: 10.1016/J.Clim.2008.03.513 |
0.609 |
|
| 2008 |
Chen JT, Collins DL, Atkins HL, Freedman MS, Arnold DL. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Annals of Neurology. 63: 254-62. PMID 18257039 DOI: 10.1002/ana.21302 |
0.303 |
|
| 2008 |
Chen Z, Freedman MS. Correlation of specialized CD16(+) gammadelta T cells with disease course and severity in multiple sclerosis. Journal of Neuroimmunology. 194: 147-52. PMID 18155780 DOI: 10.1016/J.Jneuroim.2007.11.010 |
0.581 |
|
| 2008 |
Bar-Or A, Touil T, Kebir H, Jalili F, Hilliker K, Theoret G, Bowman M, Prat A, Freedman M, Atkins H. OR.96. The Abrogation of Inflammatory Disease Activity in MS Patients Treated with Immune Ablation and Autologous Haematopoetic Stem-cell Transplantation (AHSCT) is Associated with Significant Decreases in ThIL-17, but not Th1 Responses Clinical Immunology. 127. DOI: 10.1016/J.Clim.2008.03.103 |
0.438 |
|
| 2007 |
Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, Ness J, Belman A, Boiko A, Bykova O, Waubant E, Mah JK, Stoian C, Kremenchutzky M, Bardini MR, Ruggieri M, ... ... Freedman M, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. The Lancet. Neurology. 6: 773-81. PMID 17689148 DOI: 10.1016/S1474-4422(07)70196-5 |
0.409 |
|
| 2007 |
Freedman MS. Bone marrow transplantation: does it stop MS progression? Journal of the Neurological Sciences. 259: 85-9. PMID 17560611 DOI: 10.1016/j.jns.2006.10.023 |
0.33 |
|
| 2007 |
Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim HJ, Bar-Or A. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. Journal of Immunology (Baltimore, Md. : 1950). 178: 6092-9. PMID 17475834 DOI: 10.4049/Jimmunol.178.10.6092 |
0.375 |
|
| 2007 |
Saikali P, Antel JP, Newcombe J, Chen Z, Freedman M, Blain M, Cayrol R, Prat A, Hall JA, Arbour N. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 1220-8. PMID 17267578 DOI: 10.1523/Jneurosci.4402-06.2007 |
0.678 |
|
| 2007 |
Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D, Kastrukoff L, Duquette P, Freedman M, Debouverie M, Lubetski C, et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial Annals of Neurology. 61: 14-24. PMID 17262850 DOI: 10.1002/Ana.21079 |
0.565 |
|
| 2007 |
Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R. Lack of association between antimyelin antibodies and progression to multiple sclerosis. The New England Journal of Medicine. 356: 371-8. PMID 17251533 DOI: 10.1056/Nejmoa063602 |
0.322 |
|
| 2007 |
O'Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, Robinson WH, Cherry SV, Bar-Or A, Banwell B, Fukaura H, Fukazawa T, Tenembaum S, Wong SJ, Tavakoli NP, ... ... Freedman M, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nature Medicine. 13: 211-7. PMID 17237795 DOI: 10.1038/Nm1488 |
0.395 |
|
| 2006 |
Freedman MS. Disease-modifying drugs for multiple sclerosis: current and future aspects. Expert Opinion On Pharmacotherapy. S1-9. PMID 17020427 DOI: 10.1517/14656566.7.1.S1 |
0.361 |
|
| 2006 |
O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GPA, Confavreux C, Paty DW, Stewart JA, Scheyer R. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses Neurology. 66: 894-900. PMID 16567708 DOI: 10.1212/01.Wnl.0000203121.04509.31 |
0.304 |
|
| 2006 |
Banwell B, Reder AT, Krupp L, Tenembaum S, Eraksoy M, Alexey B, Pohl D, Freedman M, Schelensky L, Antonijevic I. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 66: 472-6. PMID 16505297 DOI: 10.1212/01.Wnl.0000198257.52512.1A |
0.452 |
|
| 2006 |
Karussis D, Biermann LD, Bohlega S, Boiko A, Chofflon M, Fazekas F, Freedman M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Miller A. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting European Journal of Neurology. 13: 61-71. PMID 16420394 DOI: 10.1111/J.1468-1331.2006.01147.X |
0.43 |
|
| 2005 |
Atkins H, Freedman M. Immunoablative therapy as a treatment aggressive multiple sclerosis. Neurologic Clinics. 23: 273-300, ix. PMID 15661098 DOI: 10.1016/J.Ncl.2004.09.004 |
0.414 |
|
| 2005 |
Freedman MS, Atkins HL. Suppressing immunity in advancing MS: too much too late, or too late for much? Neurology. 62: 168-9. PMID 14745045 DOI: 10.1212/WNL.62.2.168 |
0.316 |
|
| 2004 |
Freedman MS. Primary progressive multiple sclerosis: cerebrospinal fluid considerations. Multiple Sclerosis (Houndmills, Basingstoke, England). S31-4; discussion S3. PMID 15218807 DOI: 10.1191/1352458504ms1028oa |
0.36 |
|
| 2004 |
Wolinsky JS, Kastrukoff L, Duquette P, Freedman M, O'Connor P, Debouverie M, Lubetski C, Edan G, Roullet E, Confavreux C, Thompson A, Blumhardt L, Hawkins S, Scott T, Wynn D, et al. The PROMiSe trial: baseline data review and progress report. Multiple Sclerosis Journal. 10. DOI: 10.1191/1352458504Ms1034Oa |
0.377 |
|
| 2004 |
Atkins H, Freedman M, Bowman M, Bar-Or A, Cheynier R, Corsini R, Jalili F, Kim HJ, Miller L, Sekaly R. Immune events following immunoablative therapy for the treatment of multiple sclerosis (MS) Biology of Blood and Marrow Transplantation. 10: 62. DOI: 10.1016/J.Bbmt.2003.12.023 |
0.446 |
|
| 2003 |
Pon RA, Freedman MS. Study of Herpesvirus saimiri immortalization of gammadelta T cells derived from peripheral blood and CSF of multiple sclerosis patients. Journal of Neuroimmunology. 139: 119-32. PMID 12799029 DOI: 10.1016/S0165-5728(03)00157-7 |
0.747 |
|
| 2003 |
Freedman M, King J, Oger J, Sharief M, Hartung H. Interferons in relapsing remitting multiple sclerosis The Lancet. 361: 1822-1823. PMID 12781558 DOI: 10.1016/S0140-6736(03)13419-8 |
0.473 |
|
| 2003 |
Filion LG, Graziani-Bowering G, Matusevicius D, Freedman MS. Monocyte-derived cytokines in multiple sclerosis Clinical and Experimental Immunology. 131: 324-334. PMID 12562396 DOI: 10.1046/j.1365-2249.2003.02053.x |
0.361 |
|
| 2003 |
Atkins H, Freedman M, Bowman M, Antel J, Arnold D, Bence-Bruckler I, Bar-Or A, Chen J, Cheynier R, Corsini R, Duquette P, Halpenny M, Huebsch L, Laneuville P, Lapierre Y, et al. 148Immunoablative therapy with purified autologous stem cells rescue for the treatment of poor prognosis MS Biology of Blood and Marrow Transplantation. 9: 110. DOI: 10.1016/S1083-8791(03)80149-0 |
0.427 |
|
| 2002 |
Murzenok PP, Matusevicius D, Freedman MS. gamma/delta T cells in multiple sclerosis: chemokine and chemokine receptor expression. Clinical Immunology (Orlando, Fla.). 103: 309-16. PMID 12173306 DOI: 10.1006/CLIM.2001.5213 |
0.419 |
|
| 2002 |
Jeffery D, Bashir K, Buchwald L, Coyle P, Freedman M, Markowitz C, Rammohan K, Reder T, Sharief M, Wolinsky J. Optimizing immunomodulatory therapy for MS patients: an integrated management model. Journal of the Neurological Sciences. 201: 89-90. PMID 12163200 DOI: 10.1016/S0022-510X(02)00195-8 |
0.365 |
|
| 2002 |
Freedman MS, Blumhardt LD, Brochet B, Comi G, Noseworthy JH, Sandberg-Wollheim M, Soelberg SP. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 8: 19-23. PMID 11936483 DOI: 10.1191/1352458502MS769OA |
0.332 |
|
| 2001 |
Dyment DA, Willer CJ, Scott B, Armstrong H, Ligers A, Hillert J, Paty DW, Hashimoto S, Devonshire V, Hooge J, Kastrukoff L, Oger J, Metz L, Warren S, Hader W, ... ... Freedman M, et al. Genetic susceptibility to MS: a second stage analysis in Canadian MS families. Neurogenetics. 3: 145-51. PMID 11523565 DOI: 10.1007/S100480100113 |
0.38 |
|
| 1999 |
Oger J, Freedman M. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis. Canadian Journal of Neurological Sciences. 26: 274-275. PMID 10610197 DOI: 10.1017/S0317167100000378 |
0.425 |
|
| 1998 |
Zeine R, Pon R, Ladiwala U, Antel JP, Filion LG, Freedman MS. Mechanism of gammadelta T cell-induced human oligodendrocyte cytotoxicity: relevance to multiple sclerosis. Journal of Neuroimmunology. 87: 49-61. PMID 9670845 DOI: 10.1016/S0165-5728(98)00047-2 |
0.741 |
|
| 1998 |
Francis GS, Freedman MS, Antel JP. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Multiple Sclerosis (Houndmills, Basingstoke, England). 3: 370-6. PMID 9493636 DOI: 10.1177/135245859700300602 |
0.352 |
|
| 1998 |
Zeine R, Mandy F, Freedman M. The role of NK receptors in gamma-delta T cell cytotoxicity in multiple sclerosis Journal of Neuroimmunology. 90: 79. DOI: 10.1016/S0165-5728(98)91651-4 |
0.337 |
|
| 1998 |
Pon R, Freedman M. Phenotypic and functional properties of transformed γδ T cell lines and clones from MS CSF and blood Journal of Neuroimmunology. 90: 77. DOI: 10.1016/S0165-5728(98)91637-X |
0.356 |
|
| 1998 |
Filion LG, Chabot J, Kumar A, Freedman M. Cytokine alteration of co-stimulatory molecules in MS Journal of Neuroimmunology. 90: 72. DOI: 10.1016/S0165-5728(98)91611-3 |
0.426 |
|
| 1997 |
Freedman MS, D'Souza S, Antel JP. gamma delta T-cell-human glial cell interactions. I. In vitro induction of gammadelta T-cell expansion by human glial cells. Journal of Neuroimmunology. 74: 135-42. PMID 9119966 DOI: 10.1016/S0165-5728(96)00217-2 |
0.396 |
|
| 1992 |
Freedman MS, Ruijs TC, Selin LK, Antel JP. Peripheral blood gamma-delta T cells lyse fresh human brain-derived oligodendrocytes. Annals of Neurology. 30: 794-800. PMID 1838679 DOI: 10.1002/Ana.410300608 |
0.63 |
|
| 1992 |
Freedman MS, Buu NN, Ruijs TC, Williams K, Antel JP. Differential expression of heat shock proteins by human glial cells. Journal of Neuroimmunology. 41: 231-8. PMID 1469081 DOI: 10.1016/0165-5728(92)90074-U |
0.32 |
|
| 1991 |
Yong VW, Moumdjian R, Yong FP, Ruijs TC, Freedman MS, Cashman N, Antel JP. Gamma-interferon promotes proliferation of adult human astrocytes in vitro and reactive gliosis in the adult mouse brain in vivo. Proceedings of the National Academy of Sciences of the United States of America. 88: 7016-20. PMID 1908086 DOI: 10.1073/Pnas.88.16.7016 |
0.506 |
|
| 1990 |
Ruijs TC, Freedman MS, Grenier YG, Olivier A, Antel JP. Human oligodendrocytes are susceptible to cytolysis by major histocompatibility complex class I-restricted lymphocytes. Journal of Neuroimmunology. 27: 89-97. PMID 1970580 DOI: 10.1016/0165-5728(90)90058-U |
0.524 |
|
| 1989 |
Freedman MS, Gray TA. Vascular headache: a presenting symptom of multiple sclerosis. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 16: 63-6. PMID 2924210 DOI: 10.1017/S0317167100028523 |
0.307 |
|
| 1989 |
Farmer JP, Antel JP, Freedman M, Cashman NR, Rode H, Villemure JG. Characterization of lymphoid cells isolated from human gliomas Journal of Neurosurgery. 71: 528-533. PMID 2795172 DOI: 10.3171/Jns.1989.71.4.0528 |
0.335 |
|
| 1989 |
Antel JP, Freedman MS, Brodovsky S, Francis GS, Duquette P. Activated suppressor cell function in severely disabled patients with multiple sclerosis. Annals of Neurology. 25: 204-7. PMID 2521994 DOI: 10.1002/Ana.410250219 |
0.583 |
|
| Show low-probability matches. |